Accurate, Actionable, and Affordable
Early Cancer Diagnostic Tests
MiRXES’ microRNA-centric liquid biopsy tests complement existing standard diagnostics to enable non-invasive cancer screening and early detection so that timely, life-saving care can be provided to patients.
GASTROClear
The world’s first approved* microRNA blood test for early detection of gastric cancer.
* CE IVD marked and approved for IVD use by Singapore’s Health Sciences Authority.
MiRXES GASTROClear is a qPCR-based diagnostic test kit that measures 12 microRNA biomarkers linked to gastric cancer and calculates a cancer risk score for each patient using a proprietary algorithm that has been clinically validated.
The test was developed by MiRXES in collaboration with the Singapore Gastric Cancer Consortium (SGCC), the Diagnostic Development (DxD) Hub of Singapore’s Agency for Science, Technology and Research (A*STAR), National University Hospital (NUH), and Tan Tock Seng Hospital (TTSH).
Accurate
GASTROClear is a high performance test for early detection of gastric cancer. The test detected 87.5% of stage I gastric cancers and 89.5% of stage II gastric cancers in clinical validation1.
Complementary
GASTROClear is designed to be an adjunct test to complement upper GI endoscopy, the existing gold standard for gastric cancer diagnosis, for sensitive and cost-effective gastric cancer screening.
Minimally-invasive
GASTROClear is a liquid biopsy test that assesses gastric cancer risk by measuring 12 gastric cancer-associated microRNAs from a single draw of one tube (5 milliliters) of a patient's blood.
Actionable
GASTROClear is an actionable diagnostic test for cancer screening. It gives a quantitative risk score and classifies each patient into a risk group. Clear recommendations for follow-up actions are provided in test report to help doctors manage patients.
Validated
GASTROClear has been rigorously validated in large-scale clinical studies with over 5,000 patients from Singapore and Korea. The study has been published in Gut, a leading international journal of gastroenterology and hepatology1.
Setting standards
GASTROClear sets the standard for microRNA-based diagnostic tests as an exemplar used in drafting Singapore Standard 656, the world's first national standard for design, development and validation microRNA-based diagnostics2.
1 , et al. Development and validation of a serum microRNA biomarker panel for detecting gastric cancer in a high-risk population.
2 https://www.singaporestandardseshop.sg/Product/SSPdtDetail/952ba6cf-6c1e-4712-9719-07bd5ece3f09
GASTROClear
microRNA test
GASTROClear test can be ordered by healthcare providers through MiRXES partner diagnostic labs
Tan Tock Seng Hospital (TTSH)
Molecular Diagnostic Lab (MDL)
National University Hospital (NUH)
Molecular Diagnosis Centre (MDC)
Coming soon
ParkwayHealth Laboratory
Innovative Diagnostics
GASTROClear Order Information and Product Support
For clinical diagnostic labs and healthcare providers only.
The science and story
of GASTROClear
Interview with Prof. Yeoh Khay Guan, Lead Principal Investigator of the Singapore Gastric Cancer Consortium (SGCC), and Prof. Too Heng-Phon, Co-founder of MiRXES.
Media coverage
of GASTROClear